Friday 20 November, 2009

Fluocinonide (Vanos cream) and Ciclopirox Olamine (Loprox gel): Glenmark settled patent litigation with innovator

Generic player Glenmark announced (in a press release Here ) the Paragraph IV patent litigation settlement with innovator Medicis Pharmaceutical on Fluocinonide (Vanos) cream and Ciclopirox Olamine (Loprox) gel topical formulations.

Fluocinonide (Vanos) 0.10% cream
Earlier, innovator Medicis sued Glenmark in New Jersey District Court in June, 2009 for the infringement of following Orange Book listed patents on Fluocinonide (Vanos ) 0.10% cream:

US6765001 (Assignee: Medicis Pharmaceutical; Date of Grant: July 20, 2004; Expiry Dec 21, 2021): Which covers a composition comprising One or more corticosteroids, wherein one corticosteroid comprises fluocinonide; Two or more penetration enhancers selected from the group consisting of diisopropyl adipate, dimethyl isosorbide, propylene glycol, 1,2,6-hexapetriol, and benzyl alcohol; and one or more of the group consisting of solvents and emulsifiers, wherein the penetration enhancers are present in a ratio to a total of the penetration enhancers, and solvents and emulsifiers of at least about 0.90.

US7220424 (Assignee: Medicis Pharmaceutical; Date of Grant: May 22, 2007; Expiry: Jan 7, 2023): which covers a method of delivering corticosteroids to skin comprising: Topically applying a composition comprising one or more corticosteroids with two or more penetration enhancers, and one or more of the group consisting of solvents and emulsifiers, wherein the penetration enhancers are present in ratio to a total of the penetration enhancers, and solvents and emulsifiers of at least about 0.90, and wherein the penetration enhancers comprise two or more of the group consisting of propylene glycol, diisopropyl adipate, dimethyl isosorbide, 1,2,6 hexanetriol, and benzyl alcohol

Under the terms of the Settlement Agreement, Glenmark will be able to market and distribute its generic version of Fluocinonide (Vanos cream) under license from Medicis as early as December 2013, or earlier in certain circumstances

Ciclopirox Olamine (Loprox) 0.77% Gel
Earlier, innovator Medicis sued Glenmark in New Jersey District Court for the infringement of following Orange Book listed patents on Ciclopirox Olamine (Loprox) 0.77% Gel:

US7018656 (Assignee: Aventis Pharma Deutschland ; Date of Grant: March 28, 2006; Expiry: Sep 5, 2018): which covers a gel composition comprising: at least one compound chosen from 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone and physiologically tolerable salts thereof; polyacrylic acid polymer; sodium dioctylsulfosuccinate; and 2-octyldodecanol; wherein the composition is not an emulsion.


As per terms of settlement, Glenmark will have a license to launch a generic version of Ciclopirox Olamine (Loprox) 0.77% gel, supplied by Medicis immediately.


Also, Glenmark announced (in a press release Here ) that it has entered into an agreement with pharma giant Medicis Pharmaceuticals for co-development of dosage forms for the treatment of acne vulgaris.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker